Research programme: anti-cancer antibodies - Tikro/Weizmann

Drug Profile

Research programme: anti-cancer antibodies - Tikro/Weizmann

Latest Information Update: 23 Jun 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Weizmann Institute of Science
  • Developer Tikcro Technologies; Weizmann Institute of Science
  • Class Antibodies; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 modulators; PDCD 1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 15 Jun 2015 Preclinical trials in Cancer in Israel (Parenteral)
  • 31 Dec 2014 Early research in Cancer in Israel (unspecified route) prior to December 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top